project id: TCGA-PRAD; case submitter id: TCGA-ZG-A9LS; selected normal wgs: true; source center: 23; state: released; a260 a280 ratio: 1.86; normal tumor genotype snp match: Yes; ribosomal rna 28s 16s ratio: 1.48; rna integrity number: 7.5; age at index: 64; days to birth: -23540; ethnicity: not hispanic or latino; gender: male; race: white; vital status: Alive; year of birth: 1949; age at diagnosis: 23540; ajcc clinical m: M0; ajcc clinical t: T2a; ajcc pathologic n: N1; ajcc pathologic t: T3b; classification of tumor: not reported; days to diagnosis: 0; days to last follow up: 516.0; icd 10 code: C61; last known disease status: not reported; morphology: 8140/3; primary diagnosis: Adenocarcinoma, NOS; primary gleason grade: Pattern 5; prior malignancy: no; prior treatment: No; progression or recurrence: not reported; secondary gleason grade: Pattern 4; site of resection or biopsy: Prostate gland; synchronous malignancy: No; tissue or organ of origin: Prostate gland; tumor grade: Not Reported; year of diagnosis: 2013; alcohol history: Not Reported; is ffpe: false; composition: Not Reported; days to collection: 215; initial weight: 190.0; sample id: 83c875f7-4734-434c-9417-05816fe9ce56; sample submitter id: TCGA-ZG-A9LS-01A; portion id: 94ac7bc3-454a-4e48-89cf-3c16d773f5a7; portion submitter id: TCGA-ZG-A9LS-01A-12; slide id: a9224b8c-b844-4084-909a-b1e2f0c1d645; slide submitter id: TCGA-ZG-A9LS-01A-01-TSA; percent lymphocyte infiltration: 1.0; percent monocyte infiltration: 0.0; percent necrosis: 0.0; percent neutrophil infiltration: 0.0; percent normal cells: 0.0; percent stromal cells: 0.0; percent tumor cells: 100.0; percent tumor nuclei: 65.0; section location: TOP;